Molecular imaging of apoptosis with radio-labeled annexin A5 focused on the evaluation of tumor response to chemotherapy

Anti-Cancer Agents in Medicinal Chemistry

Volumn 9, Issue 9, 2009, Pages 1003-1011

  Kuge, Yuji ^a   Zhao, Songji ^a   Takei, Toshiki ^a   Tamaki, Nagara ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Annexin A5; Apoptosis; Cancer; Chemotherapy; Molecular imaging; Radionuclide

Indexed keywords

4,5 BIS(THIOACETAMIDO)PENTANOYL ANNEXIN A5 TC 99M; ANTINEOPLASTIC AGENT; CETUXIMAB; CHELATING AGENT; CYCLOPHOSPHAMIDE; DIETHYLENETRIAMINE PENTAACETIC ACID POLYETHYLENE GLYCOL ANNEXIN A5 IN 111; DOXORUBICIN; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; GEMCITABINE; GLUCOHEPTONIC ACID; HYDRAZINONICOTINAMIDE ANNEXIN A5 (TRICINE)2 TC 99M; INDIUM 111; IODINE 124; IODINE 125; LIPOCORTIN 5; MACROGOL; N 1 IMINO 4 MERCAPTOBUTYL ANNEXIN A5 TC 99M; PACLITAXEL; PENTETATE INDIUM IN 111; PENTETIC ACID; PHOSPHATIDYLSERINE; PREDNISONE; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; TECHNETIUM 99M; TIN CHLORIDE; TIPIFARNIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE;

APOPTOSIS; B CELL LYMPHOMA; BINDING AFFINITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL SURFACE; DRUG DESIGN; DRUG EFFICACY; DRUG RESPONSE; DRUG SCREENING; DRUG STRUCTURE; HUMAN; IN VIVO STUDY; ISOTOPE LABELING; LIVER CELL CARCINOMA; MOLECULAR IMAGING; NON INVASIVE MEASUREMENT; NONHODGKIN LYMPHOMA; NONHUMAN; PROGNOSIS; REVIEW; SINGLE DRUG DOSE;

ANNEXIN A5; ANTINEOPLASTIC AGENTS; APOPTOSIS; HUMANS; NEOPLASMS; RADIOISOTOPES;

EID: 73449098139     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152009789377736     Document Type: Review

References (80)

1. Wester, H. J. Nuclear imaging probes: from bench to bedside. Clin. Cancer Res., 2007, 13, 3470-3481.
2. Nijsen, J. F.; Krijger, G. C.; van Het Schip, A. D. The bright future of radionuclides for cancer therapy. Anticancer Agents Med. Chem., 2007, 7, 271-290.
3. Thompson, C. B. Apoptosis in the pathogenesis and treatment of disease. Science, 1995, 267, 1456-1462.
4. Evan, G. I.; Vousden, K. H. Proliferation, cell cycle and apoptosis in cancer. Nature, 2001, 411, 342-348.
5. Kerr, J. F.; Winterford, C. M.; Harmon, B. V. Apoptosis. Its significance in cancer and cancer therapy. Cancer, 1994, 73, 2013-2026.
6. Blankenberg, F. G. In vivo imaging of apoptosis. Cancer Biol. Ther., 2008, 7, 1525-1532.
7. Blankenberg, F. G. In vivo detection of apoptosis. J. Nucl. Med., 2008, 49 (Suppl 2), 81S-95S.
8. Lahorte, C. M.; Vanderheyden, J. L.; Steinmetz, N.; Van de Wiele, C.; Dierckx, R. A.; Slegers, G. Apoptosis-detecting radioligands: current state of the art and future perspectives. Eur. J. Nucl. Med. Mol. Imaging, 2004, 31, 887-919.
9. Van de Wiele, C.; Vermeersch, H.; Loose, D.; Signore, A.; Mertens, N.; Dierckx, R. Radiolabeled annexin-V for monitoring treatment response in oncology. Cancer Biother. Radiopharm., 2004, 19, 189-194.
10. 99mTc-Annexin A5 uptake and imaging to monitor chemosensitivity. Methods Mol. Med., 2005, 111, 363-380.
11. Fadok, V. A.; Voelker, D. R.; Campbell, P. A.; Cohen, J. J.; Bratton, D. L.; Henson, P. M. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J. Immunol., 1992, 148, 2207-2216.
12. Zwaal, R. F.; Schroit, A. J. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood, 1997, 89, 1121-1132.
13. Gerke, V.; Moss, S. E. Annexins: from structure to function. Physiol. Rev., 2002, 82, 331-371.
14. Thiagarajan, P.; Tait, J. F. Binding of annexin V/placental anticoagulant protein I to platelets. Evidence for phosphatidylserine exposure in the procoagulant response of activated platelets. J. Biol. Chem., 1990, 265, 17420-17423.
15. Tait, J. F.; Gibson, D.; Fujikawa, K. Phospholipid binding properties of human placental anticoagulant protein-I, a member of the lipocortin family. J. Biol. Chem., 1989, 264, 7944-7949.
16. Andree, H. A.; Reutelingsperger, C. P.; Hauptmann, R.; Hemker, H. C.; Hermens, W. T.; Willems, G. M. Binding of vascular anticoagulant alpha (VAC alpha) to planar phospholipid bilayers. J. Biol. Chem., 1990, 265, 4923-4928.
17. van Heerde, W. L.; de Groot, P. G.; Reutelingsperger, C. P. The complexity of the phospholipid binding protein Annexin V. Thromb. Haemost., 1995, 73, 172-179.
18. Boersma, H. H.; Kietselaer, B. L.; Stolk, L. M.; Bennaghmouch, A.; Hofstra, L.; Narula, J.; Heidendal, G. A.; Reutelingsperger, C. P. Past, present, and future of annexin A5: from protein discovery to clinical applications. J. Nucl. Med., 2005, 46, 2035-2050.
19. Koopman, G.; Reutelingsperger, C. P.; Kuijten, G. A.; Keehnen, R. M.; Pals, S. T.; van Oers, M. H. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood, 1994, 84, 1415-1420.
20. van Engeland, M.; Nieland, L. J.; Ramaekers, F. C.; Schutte, B.; Reutelingsperger, C. P. Annexin V-affinity assay: a review on an apoptosis detection system based on phosphatidylserine exposure. Cytometry, 1998, 3, 1-9.
21. 123I-rh-annexin V in mice and humans. Nuclear Med. Commun., 2003, 24, 871-880.
22. Wen, X.; Wu, Q. P.; Ke, S.; Wallace, S.; Charnsangavej, C.; Huang, P.; Liang, D.; Chow, D.; Li, C. Improved radiolabeling of PEGylated protein: PEGylated annexin V for noninvasive imaging of tumor apoptosis. Cancer Biother. Radiopharm., 2003, 18, 819-827.
23. 18F-labelled recombinant annexin-V derivative, for identification and quantification of apoptotic cells with PET. Appl. Radiat. Isot., 2003, 58, 201-207.
24. Grierson, J. R.; Yagle, K. J.; Eary, J. F.; Tait, J. F.; Gibson, D. F.; Lewellen, B.; Link, J. M.; Krohn, K. A. Production of [F-18]fluoroannexin for imaging apoptosis with PET. Bioconjug. Chem., 2004, 15, 373-379.
25. 18F-labelled annexin V: a PET tracer for apoptosis imaging. Eur. J. Nucl. Med. Mol. Imaging, 2004, 31, 469-474.
26. Toretsky, J.; Levenson, A.; Weinberg, I. N.; Tait, J. F.; Uren, A.; Mease, R. C. Preparation of F-18 labeled annexin V: a potential PET radiopharmaceutical for imaging cell death. Nucl. Med. Biol., 2004, 31, 747-752.
27. Li, X.; Link, J. M.; Stekhova, S.; Yagle, K. J.; Smith, C.; Krohn, K. A.; Tait, J. F. Site-specific labeling of annexin V with F-18 for apoptosis imaging. Bioconjug. Chem., 2008, 19, 1684-1688.
28. 124I-annexin V and PET. Nucl. Med. Biol., 2005, 32, 395-402.
29. Glaser, M.; Collingridge, D. R.; Aboagye, E. O.; Bouchier-Hayes, L.; Hutchinson, O. C.; Martin, S. J.; Price, P.; Brady, F.; Luthra, S. K. Iodine-124 labelled annexin-V as a potential radiotracer to study apoptosis using positron emission tomography. Appl. Radiat. Isot., 2003, 58, 55-62.
30. Stratton, J. R.; Dewhurst, T. A.; Kasina, S.; Reno, J. M.; Cerqueira, M. D.; Baskin, D. G.; Tait, J. F. Selective uptake of radiolabeled annexin V on acute porcine left atrial thrombi. Circulation, 1995, 92, 3113-3121.
31. 99mTc-annexin A5. Br. J. Radiol., 2003, 76, 553-560.
32. 99mTc-BTAP-annexin-V in humans. Eur. J. Nucl. Med. Mol. Imaging, 2001, 28, 1373-1378.
33. Blankenberg, F. G.; Katsikis, P. D.; Tait, J. F.; Davis, R. E.; Naumovski, L.; Ohtsuki, K.; Kopiwoda, S.; Abrams, M. J.; Darkes, M.; Robbins, R. C.; Maecker, H. T.; Strauss, H. W. In vivo detection and imaging of phosphatidylserine expression during programmed cell death. Proc. Natl. Acad. Sci. USA, 1998, 95, 6349-6354.
34. Abrams, M. J.; Juweid, M.; tenKate, C. I.; Schwartz, D. A.; Hauser, M. M.; Gaul, F. E.; Fuccello, A. J.; Rubin, R. H.; Strauss, H. W.; Fischman, A. J. Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats. J. Nucl. Med., 1990, 31, 2022-2028.
35. Blankenberg, F. G.; Vanderheyden, J. L.; Strauss, H. W.; Tait, J. F. Radiolabeling of HYNIC-annexin V with technetium-99m for in vivo imaging of apoptosis. Nat. Protoc., 2006, 1, 108-110.
36. 99mTc-annexin V. J. Nucl. Med., 2001, 42, 382-387.
37. Hofstra, L.; Liem, I. H.; Dumont, E. A.; Boersma, H. H.; van Heerde, W. L.; Doevendans, P. A.; De Muinck, E.; Wellens, H. J.; Kemerink, G. J.; Reutelingsperger, C. P.; Heidendal, G. A. Visualisation of cell death in vivo in patients with acute myocardial infarction. Lancet, 2000, 356, 209-212.
38. 99mTc-MAG3-annexin V: influence of the chelate on in vitro and in vivo properties in mice. Nucl. Med. Biol., 2006, 33, 135-144.
39. 99mTc-labeled Hynic-derivatized Annexin V for human use. Nucl. Med. Biol., 2003, 30, 771-778.
40. Zhang, Y. M.; Liu, N.; Zhu, Z. H.; Rusckowski, M.; Hnatowich, D. J. Influence of different chelators (HYNIC, MAG3 and DTPA) on tumor cell accumulation and mouse biodistribution of technetium-99m labeled to antisense DNA. Eur. J. Nucl. Med., 2000, 27, 1700-1707.
41. 99mTc-neutrophil elastase inhibitor in monkeys. J. Nucl. Med., 2000, 41, 363-374.
42. 99mTc-annexin V. J. Nucl. Med., 2005, 46, 807-815.
43. 99mTc. Bioconjug. Chem., 2000, 11, 918-925.
44. Jin, M.; Smith, C.; Hsieh, H. Y.; Gibson, D. F.; Tait, J. F. Essential role of B-helix calcium binding sites in annexin V-membrane binding. J. Biol. Chem., 2004, 279, 40351-40357.
45. Tait, J. F.; Smith, C.; Levashova, Z.; Patel, B.; Blankenberg, F. G.; Vanderheyden, J. L. Improved detection of cell death in vivo with annexin V radiolabeled by site-specific methods. J. Nucl. Med. 2006, 47, 1546-1553.
46. 99mTc-radiolabeled annexin V. J. Nucl. Med., 2001, 42, 309-316.
47. 99mTc-annexin V. J. Nucl. Med., 2003, 44, 92-97.
48. 99mTc-annexin V uptake and histologic findings in an experimental model. J. Nucl. Med., 2004, 45, 2083-2087.
49. 18F-FDG, and histologic evaluation. J. Nucl. Med., 2005, 46, 794-799.
50. 99mTc-EC-annexin V. Cancer Biother. Radiopharm., 2001, 16, 73-83.
51. 99mTc-annexin V for repetitive detection of apoptotic tumor response to chemotherapy: an experimental study using a rat tumor model. J. Nucl. Med., 2004, 45, 309-312.
52. 99mTc- annexin V and its biologic evaluation for in vivo imaging of apoptosis after photodynamic therapy. J. Nucl. Med., 2003, 44, 650-656.
53. Cohade, C.; Wahl, R. L. PET scanning and measuring the impact of treatment. Cancer J., 2002, 8, 119-134.
54. Rohren, E. M.; Turkington, T. G.; Coleman, R. E. Clinical applications of PET in oncology. Radiology, 2004, 231, 305-332.
55. Brun, E.; Kjellen, E.; Tennvall, J.; Ohlsson, T.; Sandell, A.; Perfekt, R.; Wennerberg, J.; Strand, S. E. FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma. Head Neck, 2002, 24, 127-135.
56. 18F]FDG for therapy response monitoring in lymphoma patients. Eur. J. Nucl. Med. Mol. Imaging, 2003, 30 (Suppl 1), S97-105.
57. Cornelissen, B.; Lahorte, C.; Kersemans, V.; Capriotti, G.; Bonanno, E.; Signore, A.; Van de Wiele, C.; Dierckx, R. A.; Slegers, G. In vivo apoptosis detection with radioiodinated Annexin V in LoVo tumour-bearing mice following Tipifarnib (Zarnestra, R115777) farnesyltransferase inhibitor therapy. Nucl. Med. Biol., 2005, 32, 233-239.
58. Dechsupa, S.; Kothan, S.; Vergote, J.; Leger, G.; Martineau, A.; Berangeo, S.; Kosanlavit, R.; Moretti, J. L.; Mankhetkorn, S. Quercetin, Siamois 1 and Siamois 2 induce apoptosis in human breast cancer MDA-mB-435 cells xenograft in vivo. Cancer Biol. Ther., 2007, 6, 56-61.
59. Kim, W.; Yoon, J. H.; Jeong, J. M.; Cheon, G. J.; Lee, T. S.; Yang, J. I.; Park, S. C.; Lee, H. S. Apoptosis-inducing antitumor efficacy of hexokinase II inhibitor in hepatocellular carcinoma. Mol. Cancer Ther., 2007, 6, 2554-2562.
60. 111In-labeled annexin V. J. Nucl. Med., 2004, 45, 108-115.
61. Adjei, A. A. Blocking oncogenic Ras signaling for cancer therapy. J. Natl. Cancer Inst., 2001, 93, 1062-1074.
62. Favoni, R. E.; de Cupis, A. The role of polypeptide growth factors in human carcinomas: new targets for a novel pharmacological approach. Pharmacol. Rev., 2000, 52, 179-206.
63. Gwak, G. Y.; Yoon, J. H.; Kim, K. M.; Lee, H. S.; Chung, J. W.; Gores, G. J. Hypoxia stimulates proliferation of human hepatoma cells through the induction of hexokinase II expression. J. Hepatol., 2005, 42, 358-64.
64. 99mTc-HYNIC-annexin V, a novel human recombinant annexin V for human application. J. Nucl. Med., 2003, 44, 947-952.
65. van de Wiele, C.; Lahorte, C.; Vermeersch, H.; Loose, D.; Mervillie, K.; Steinmetz, N. D.; Vanderheyden, J. L.; Cuvelier, C. A.; Slegers, G.; Dierck, R. A. Quantitative tumor apoptosis imaging using technetium-99m-HYNIC annexin V single photon emission computed tomography. J. Clin. Oncol., 2003, 21, 3483-3487.
66. 99mTc recombinant human Annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis. Clin. Cancer Res., 2002, 8, 2766-2774.
67. 99mTc-Annexin V scintigraphy: visual analysis in relation to treatment response. Radiother. Oncol., 2004, 72, 333-339.
68. 99mTc-Hynic-rh- annexin V SPECT and CT image fusion. Eur. J. Nucl. Med. Mol. Imaging, 2006, 33, 893-899.
69. 99mTc Hynic-rh-annexin V scintigraphy during platinum-based chemotherapy in advanced lung cancer. J. Clin. Oncol., 2007, 25, 2534-2539.
70. 99mTc Hynic-rh-Annexin V scintigraphy for in vivo imaging of apoptosis in patients with head and neck cancer treated with chemoradiotherapy. Eur. J. Nucl. Med. Mol. Imaging, 2008, 35, 509-518.
71. 99mTc-HYNIC-rh-annexin-V scintigraphy: visual and quantitative evaluation of early treatment-induced apoptosis to predict treatment outcome. Nuclear Med. Commun., 2008, 29, 39-44.
72. 18F-FDG PET/CT and apoptosis induced by neoadjuvant chemotherapy in breast cancer. Cancer Biol. Ther., 2007, 6, 1442-1448.
73. Blankenberg, F. To scan or not to scan, it is a question of timing: technetium-99m-annexin V radionuclide imaging assessment of treatment efficacy after one course of chemotherapy. Clin. Cancer Res., 2002, 8, 2757-2758.
74. Belhocine, T.; Steinmetz, N.; Li, C.; Green, A.; Blankenberg, F. G. The imaging of apoptosis with the radiolabeled annexin V: optimal timing for clinical feasibility. Technol. Cancer. Res. Treat., 2004, 3, 23-32.
75. Hofstra, L.; Dumont, E. A.; Thimister, P. W.; Heidendal, G. A.; DeBruine, A. P.; Elenbaas, T. W.; Boersma, H. H.; van Heerde, W. L.; Reutelingsperger, C. P. In vivo detection of apoptosis in an intracardiac tumor. JAMA, 2001, 285, 1841-1842.
76. Haas, R. L.; de Jong, D.; Valdes Olmos, R. A.; Hoefnagel, C. A.; van den Heuvel, I.; Zerp, S. F.; Bartelink, H.; Verheij, M. In vivo imaging of radiation-induced apoptosis in follicular lymphoma patients. Int. J. Radiat. Oncol. Biol. Phys., 2004, 59, 782-787.
77. 99mTc-HYNIC annexin-V imaging in head and neck carcinoma. Cancer Biother. Radiopharm., 2004, 19, 205-210.
78. 99mTc-HYNIC annexin V uptake to microvessel density, FasL and MMP-9 expression, and the number of tumour-infiltrating lymphocytes in head and neck carcinoma. Eur. J. Nucl. Med. Mol. Imaging, 2004, 31, 1016-1021.
79. 99mTc-hydrazinonicotinamide-annexin V imaging for predicting response to chemotherapy. J. Nucl. Med. 2006, 47, 1813-1818.
80. 99mTc-HYNIC Annexin-V imaging of tumors and its relationship to response to radiotherapy and/or chemotherapy. Q. J. Nucl. Med. Mol. Imaging, 2007, 51, 182-188.